11:I[469896,["/_next/static/chunks/1--abj19ag76a.js","/_next/static/chunks/1ntn7efqc-iiw.js","/_next/static/chunks/1yesdmqynxwjj.js","/_next/static/chunks/09-1q0lr7fef5.js","/_next/static/chunks/2j9j20l3evo8o.js","/_next/static/chunks/34686_nv0omha.js","/_next/static/chunks/2la3dtgl28y3n.js"],"default"] 12:I[389413,["/_next/static/chunks/1--abj19ag76a.js","/_next/static/chunks/1ntn7efqc-iiw.js","/_next/static/chunks/1yesdmqynxwjj.js","/_next/static/chunks/09-1q0lr7fef5.js","/_next/static/chunks/2j9j20l3evo8o.js","/_next/static/chunks/34686_nv0omha.js","/_next/static/chunks/2la3dtgl28y3n.js"],"default"] :HL["/themes/ijsrm.css","style"] 13:T486,

Background: The polycaprolactone-based filler, (PCL-1, Ellansé-M) has been widely used for the treatment of various facial regions, both for volume enhancement and skin rejuvenation. Thus far, reports on the outcomes of PCL-based dermal fillers for the infraorbital area are limited.

Objective: To assess the aesthetic outcomes related to the infraorbital area using a PCL-based dermal filler over a one-year post-treatment period.

Materials and Methods: The study population consisted of 10 patients (100% women) aged between 45 and 65 years, undergoing infraorbital treatment with a PCL-based dermal filler in a private clinic. The authors employed the grading system based on the volume difference between pre- and post-injection photographs to evaluate its efficacy at 1- and 12-months post-procedure.

Results: The average evaluation scores at 1 and 12 months were 1.5 and 1.8, respectively. The mean improvement on the clinical GAIS scale was observed in all participants one year after the procedure. A clear increase in volume of the infraorbital area were observed in all patients at one year.

Viviane Souto Spadoni